US 12,447,143 B2
Microsphere-based injectable celecoxib formulation
Ang Li, New York, NY (US)
Assigned to Avidence Therapeutics, Inc., New York, NY (US)
Filed by Avidence Therapeutics, Inc., New York, NY (US)
Filed on Jan. 23, 2025, as Appl. No. 19/034,843.
Application 19/034,843 is a continuation of application No. 17/629,822, previously published as PCT/US2020/045099, filed on Aug. 6, 2020.
Claims priority of provisional application 62/884,526, filed on Aug. 8, 2019.
Prior Publication US 2025/0161272 A1, May 22, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/415 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 47/10 (2017.01); A61P 19/02 (2006.01)
CPC A61K 31/415 (2013.01) [A61K 9/0019 (2013.01); A61K 9/16 (2013.01); A61K 47/10 (2013.01); A61P 19/02 (2018.01)] 15 Claims
 
1. A plurality of biodegradable microspheres, wherein the microspheres (i) have a d90 value from 20 μm to 150 μm; (ii) comprise a polylactic-co-glycolic acid copolymer (PLGA) matrix having a lactic acid to glycolic acid molar ratio of 75:25; (iii) carry a therapeutically effective amount of pharmaceutical celecoxib at a celecoxib loading of 62.7% or 62.8% by weight (calculated as celecoxib/(celecoxib+PLGA)); and (iv) when present in a suitable joint-related tissue, continuously release celecoxib for at least three months, wherein the celecoxib released per day is from 0.2X mg to 5X mg during the at least three months, where X mg is the average celecoxib released per day, and wherein the PLGA is ester terminated and has a viscosity of 0.9 dl/g.